Also known as: fatty liver disease
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Researchers have discovered that vitamin B3 (niacin) can effectively target microRNA-93, a key genetic driver of fatty liver disease. The study shows niacin reduces miR-93 levels and increases SIRT1 activity, restoring normal fat-processing pathways in the liver. This finding suggests a widely available vitamin could become a new treatment for metabolic-associated fatty liver disease affecting 30% of people globally.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07644936 |
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach |
NOT_YET_RECRUITING | |
| NCT07403604 |
Effect of Insulin Lowering on Lipogenesis |
RECRUITING | PHASE1 |
| NCT07358546 |
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment |
RECRUITING | PHASE1 |
| NCT07335198 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07294963 |
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease |
COMPLETED | NA |
| NCT07221227 |
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH |
RECRUITING | PHASE3 |
| NCT07221188 |
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH |
RECRUITING | PHASE3 |
| NCT06920043 |
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH |
RECRUITING | PHASE2 |
| NCT06571474 |
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) |
RECRUITING | |
| NCT06482112 |
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) |
COMPLETED | PHASE2 |
